AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Autonomic and Renal Contributions to Hypertension With ADT

RecruitingPhase 4Ages 40 Years - anyMaleVirginia Commonwealth University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * age 40+ years; * resting blood pressure \<140/90 mmHg; * fasted blood glucose \<126 mg/dL; * testosterone โ‰ฅ400 ng/dL; * sedentary to recreationally active; * nonsmokers; * healthy as determined by medical history, physical exam, blood and urine chemistries and resting and exercise ECG during a physician supervised graded exercise treadmill test OR recent diagnosis of non-metastatic prostate cancer with plans to undergo androgen deprivation therapy; * PSA \<4.00 ng/dL if in the non-cancer group; * Gleason Score โ‰ค7 if in the prostate cancer group; * no use of medications that might influence cardiovascular function (e.g., antihypertensives, lipid-lowering medications); * willing and able to be on GnRHagonist and AR inhibitor; * not taking antioxidant vitamins, corticosteroids, or anti-inflammatory medications, or willing to stop use for four weeks prior to the start of the study; * not using exogenous sex hormones for at least one year Exclusion Criteria: * -acute liver disease; * chronic kidney disease, serum creatinine \>1.3 mg/dL, macroalbuminuria \>300 mg/g of proteinuria * pre-existing or active cardiac, renal or hepatic disease, epilepsy or other seizure disorder; * diabetes, active or chronic infection, disease that affects the nervous system; * Gleason Score โ‰ฅ8; * thyroid dysfunction, defined as ultrasensitive TSH \<0.5 or \>5.0 mU/L, volunteers with abnormal TSH values will be re-considered for participation after follow-up evaluation by the PCP with initiation or adjustment of thyroid hormone replacement; * tobacco use within the previous 12 months
๐Ÿ’Š

What it tests

  • Gonadotropin Releasing Hormone Agonists (GNRH)
  • Androgen receptor (AR) inhibitor
  • Placebo
๐Ÿ“

Where

1 site
Virginia Commonwealth University
Richmond, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy